This Week in Pulmonary — May 14, 2026

Welcome to This Week in Pulmonary. This week we're covering 9 notable papers spanning advances in COPD management, new insights into asthma progression, and the growing role of precision diagnostics across the specialty. We'll also touch on the long-term sequelae of tuberculosis. Let's dive in.

First, we turn to COPD, with three papers that span the full spectrum of the disease, from its earliest origins to the nuances of triple therapy in advanced cases. A narrative review in the International Journal of Chronic Obstructive Pulmonary Disease provides a framework for understanding the disease before it becomes spirometrically apparent [1]. It focuses on the concept of the pulmonary "Silent Zone," where small airway disease—including terminal bronchiole loss and mucus plugging—is already developing. This pre-COPD phase, which also includes phenotypes like PRISm and non-obstructive chronic bronchitis, is often missed by the standard FEV1/FVC cutoff. The authors argue that a focus on this silent zone, using tools like impulse oscillometry and advanced CT analysis, could improve early risk stratification and potentially modify the disease course before irreversible obstruction occurs.

For patients with more advanced disease, two studies this week, also in the International Journal of Chronic Obstructive Pulmonary Disease, examine the real-world use of triple therapy. The first is a retrospective cohort study looking at outcomes after initiating triple therapy during or shortly after a hospitalization for a severe COPD exacerbation [2].

Results In the overall cohort of 500 patients, initiating triple therapy did not lead to a significant difference in three-year COPD-related readmission or all-cause mortality. This is a critical finding, suggesting that routine initiation in all post-hospitalization patients may not be warranted.

Subgroup Analysis However, the story is more complex. In a stratified analysis, the authors found a significant benefit in a high-risk subgroup: patients who had two or more exacerbations in the year before their hospitalization saw a dramatic reduction in the risk of both readmission and mortality with triple therapy. This highlights the importance of patient selection.

While that study questioned *when* to start triple therapy, a second large observational study from the United Kingdom asked *which* triple therapy to choose [5]. This real-world study compared two commonly prescribed single-inhaler triple therapies: once-daily fluticasone-umeclidinium-vilanterol, or FUV, and twice-daily beclomethasone-glycopyrronium-formoterol, or BEGF.

Efficacy After balancing for baseline characteristics, initiating treatment with the once-daily FUV was associated with a nearly 10% lower rate of moderate or severe exacerbations compared to BEGF. This corresponded to preventing an exacerbation in about 28 out of every 100 patients treated for one year.

Safety However, this came with a potential safety trade-off. The risk of severe pneumonia requiring hospitalization was slightly higher with FUV, particularly among patients classified as GOLD Group E or those with blood eosinophil counts at or below 300 cells per microliter. In these groups, the increased risk corresponded to about 1 to 2 additional cases of severe pneumonia per 100 patients treated for a year. Together, these studies [2, 5] suggest a more nuanced approach to triple therapy, where patient selection and the specific agent chosen involve a careful weighing of exacerbation history, eosinophil levels, and the trade-off between efficacy and pneumonia risk.

Next, we move to asthma, with two papers from the American Journal of Respiratory and Critical Care Medicine that explore who develops severe disease and the complex biology at the mucosal level. The first study aimed to identify risk factors for progression from mild-to-moderate to severe asthma [8].

The Study Using a large Danish national database, investigators followed nearly 100,000 adults with mild-to-moderate asthma after their first exacerbation to see who progressed to severe disease within five years.

Results Reassuringly, the overall risk of progression was low, at just 4.1%. However, the study identified a specific high-risk profile. Factors for progression included being 40 to 49 years old, having an exacerbation despite being on medium-dose inhaled corticosteroids, high SABA use, recurrent respiratory infections, and a blood eosinophil count of 600 or more. For a patient with this combination of risk factors, the five-year risk of progressing to severe asthma was not 4%, but over 30%. This finding could help clinicians identify patients who may warrant closer monitoring or earlier intervention.

But what's happening in the airways to drive this? A second study provides a fascinating look at the spatial organization of the airway mucosa in asthma [3].

Methods Investigators performed bronchoscopy on asthmatics and healthy controls, using advanced techniques like 16S rRNA gene sequencing and Digital Spatial Profiling to map out the relationships between microbes, host gene expression, and histology within the airway wall.

Key Findings The results paint a complex picture. Clinical asthma was independently predicted by a combination of basement membrane abnormalities, overall bacterial diversity, and circulating eosinophil counts—but not by the abundance of any single bacterial species. Using in-situ hybridization, the team found bacteria physically present within the epithelial and stromal layers of the mucosa in all subjects, including healthy controls. Interestingly, the presence of these intra-mucosal bacteria was associated with a *down-regulation* of immune pathways related to antigen presentation and neutrophil function. This suggests that a diverse microbiome residing within the mucosa may actually play a beneficial, immune-modulating role. This complex interplay of structural changes, microbial communities, and immune responses underscores that asthma pathogenesis extends far beyond simple eosinophilic inflammation.

Our third theme highlights the drive towards personalized medicine, with three studies showcasing novel tools to refine risk stratification and predict treatment response. First, a study in Chest validates a deep learning model called Sybil for lung cancer risk prediction [4]. Sybil analyzes a single low-dose chest CT to predict a person's risk of developing lung cancer over the next one to six years. This study tested its performance in a large, pragmatic Asian screening cohort of over 21,000 individuals, including a large proportion of people who had never smoked.

Performance Sybil performed well, achieving an area under the curve, or AUROC, of 0.86 for predicting lung cancer within one year. Its performance was particularly notable in individuals who have never smoked, with an AUROC of 0.86 for one-year prediction and 0.79 for six-year prediction. The model's performance was less robust in patients with subsolid nodules or findings of granulomatous sequelae, but these results support the potential for AI-driven, personalized lung cancer screening strategies tailored to different risk profiles.

From predicting risk in cancer screening, we turn to predicting treatment response in cystic fibrosis. A paper in Thorax addresses the challenge that patients with identical CFTR genotypes can have widely varied responses to modulator therapy [7].

The Study Investigators cultured human nasal epithelial cells from 24 pediatric patients. In the lab, they measured the functional response of these cells to CFTR modulators, quantified as a change in short-circuit current, or delta Isc.

Results They found a strong linear relationship between this lab-based measurement and the patients' actual clinical response. The delta Isc from the nasal cells was highly predictive of both improvement in FEV1 and reduction in sweat chloride. For predicting a combined clinical response in patients with baseline FEV1 less than 90%, the test had a perfect AUC of 1.00 in this cohort. This work demonstrates that a patient-derived cell-based assay can serve as a robust predictive tool to guide personalized modulator selection, potentially avoiding ineffective therapy.

Sticking with the theme of using nasal samples for diagnostics, a study in the European Respiratory Journal evaluated a tool for screening for primary ciliary dyskinesia, or PCD [6]. PCD is a known but underdiagnosed genetic cause of bronchiectasis. The study prospectively enrolled 373 adults with bronchiectasis and used nasal nitric oxide measurement as a screening tool. Individuals with a low nasal nitric oxide level or high clinical suspicion underwent a full diagnostic workup.

Key Findings The results were striking. A total of 7.4% of this adult bronchiectasis cohort were diagnosed with confirmed or highly likely PCD. Nasal nitric oxide measurement proved to be a highly accurate screening test, with a sensitivity of about 85% and a specificity of 97%. The authors conclude that this simple, non-invasive measurement, combined with clinical features, is an effective and reliable strategy to screen for PCD in patients with bronchiectasis, a population in whom the diagnosis is often missed.

Finally, a study in the American Journal of Respiratory and Critical Care Medicine expands our understanding of the long-term consequences of tuberculosis [9]. While post-pulmonary TB lung disease is well-recognized, the pulmonary sequelae in patients treated for extra-pulmonary tuberculosis, or EPTB, have been unknown.

The Study Researchers in India performed spirometry on 275 adults who had been successfully treated for EPTB, comparing them to survivors of pulmonary TB and to healthy household controls. Lung function was assessed at the end of treatment and followed for 1.5 years.

Results Compared to controls, survivors of EPTB had significantly lower FEV1 and FVC z-scores at the end of treatment. They had more than double the odds of having a restrictive pattern on spirometry. These lung function deficits were associated with respiratory symptoms and persisted throughout the 1.5-year follow-up period. While the severity was less than that seen in post-pulmonary TB patients, the findings clearly demonstrate that EPTB is not a benign entity for the lungs. The authors recommend that patients treated for EPTB should be screened for post-tuberculosis lung disease.

If you only have time for one paper this week, make it the real-world comparison of single-inhaler triple therapies in COPD from the International Journal of Chronic Obstructive Pulmonary Disease [5]. This large observational study provides actionable data on the relative benefits and risks of two commonly used inhalers, highlighting a key trade-off between exacerbation prevention and pneumonia risk that will directly inform clinical decision-making.

Here are the key takeaways from this week in Pulmonary. First: In COPD, initiating triple therapy after a hospitalization may only benefit high-risk patients, such as those with frequent exacerbations. When choosing a triple therapy, once-daily fluticasone-umeclidinium-vilanterol may offer better exacerbation protection than twice-daily beclomethasone-glycopyrronium-formoterol, but carries a higher pneumonia risk in GOLD E patients or those without eosinophilia [2, 5]. Second: While most patients with mild-to-moderate asthma do not progress to severe disease after a first exacerbation, clinicians should be alert to a high-risk profile—particularly middle-aged patients with late-onset eosinophilic disease and recurrent infections—who face a risk as high as 30% [8]. Third: The nose is proving to be a valuable window to the lungs. Nasal nitric oxide is an effective screening tool for PCD in patients with bronchiectasis [6], and nasal epithelial cell cultures show great promise in predicting response to CFTR modulators in pediatric CF [7]. Fourth: Remember that extra-pulmonary tuberculosis is not just an extra-pulmonary disease. Patients successfully treated for EPTB have persistent lung function deficits and should be screened for post-tuberculosis lung disease [9].

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.